Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment. Cardiac ...

Background Hereditary transthyretin amyloidosis (ATTRv) is a rare multisystem disorder with marked phenotypic heterogeneity.

Amyloidosis occurs when the body produces abnormal proteins that bind together to form a substance called amyloid. Amyloids can deposit in any tissue or organ, including the heart, kidneys, liver and ...

Please provide your email address to receive an email when new articles are posted on . Many patients with amyloidosis take years to be diagnosed. New ASH guidelines make 12 recommendations to improve ...

Transthyretin amyloidosis (ATTR) prognosis can vary based on several factors, including the type you have, how early you were diagnosed, whether you have heart failure symptoms, and whether you have ...

The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...

Uncover the latest and most impactful research in Amyloidosis Diagnosis and Treatment Strategies. Explore pioneering discoveries, insightful ideas and new methods from leading researchers in the field ...

A new review paper was published in Oncotarget, titled "Systemic AL amyloidosis: current approach and future direction." In this review, researchers from SUNY Upstate Medical University, University of ...

A case report describes an exceptionally rare instance of wild-type transthyretin amyloidosis confined to the ...

This weekend is the Richard S. Caliguiri Great Race, named for the late former Pittsburgh mayor.

Transthyretin-mediated (ATTR) amyloidosis is a multisystem disease caused by the abnormal deposition of misfolded transthyretin protein as amyloid fibrils in various tissues. ATTR amyloidosis presents ...